Breakthroughs in mRNA purification could redefine vaccine and therapeutic quality
A webinar is set to explore the latest advancements in mRNA quantitation and purification. Kelsey Swingle, PhD, from Rice University, will kickstart the event with an overview of mRNA lipid nanoparticle (LNP) therapeutics. Nathaniel Clark, PhD, Senior Scientist at Repligen, will also participate, discussing emerging techniques for mRNA therapeutics beyond COVID-19 vaccines.
One of the key challenges in mRNA-based vaccines and therapeutics is the presence of immunogenic double-stranded RNA (dsRNA) byproducts. These impurities complicate purification processes and can trigger immune responses. The webinar will investigate the potential of in-line variable pathlength technology to enhance mRNA manufacturing, with a focus on size determination and quantification of dsRNA contaminants.
Current ultraviolet (UV) methods of nucleic acid quantitation require additional sample handling, which can lead to inaccuracies in measuring mRNA concentration. The webinar will present the validation of variable path length technology for accurate, reproducible mRNA quantitation, eliminating the need for extra sample handling. A dsRNA-specific affinity chromatography resin will also be discussed, which effectively removes dsRNA byproducts and suppresses immune responses in cell-based assays.
The webinar, titled 'Advancements in mRNA Quantitation and Purification', will provide insights into improving mRNA manufacturing and ensuring consistent purity and quality. It will cover emerging techniques for mRNA therapeutics beyond COVID-19 vaccines and include a live Q&A session for attendees to interact with the expert panelists.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Sleep Maxxing Trends and Tips: New Zealanders Seek Better Rest
- Over 1.7M in Baden-Württemberg at Poverty Risk, Emmendingen's Housing Crisis Urgent
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
